Recombinant	JJ	recombinant O TermTag
human	JJ	human O TermTag
serum	NN	serum GENE TermTag
amyloid	NN	amyloid GENE TermTag
P	NN	P GENE TermTag
in	IN	in O TermTag
healthy	JJ	healthy O TermTag
volunteers	NNS	volunteer O TermTag
and	CC	and O TermTag
patients	NNS	patient O TermTag
with	IN	with O TermTag
pulmonary	JJ	pulmonary O TermTag
fibrosis	NN	fibrosis O TermTag
.	.	. . NUPOS

PRM-151	NN	PRM-151 O TermTag
,	,	, , NUPOS
recombinant	JJ	recombinant O TermTag
human	JJ	human O TermTag
Pentraxin-2	NN	Pentraxin-2 GENE TermTag
(	(	( ( NUPOS
PTX-2	NN	PTX-2 GENE TermTag
)	)	) ) NUPOS
also	RB	also O TermTag
referred	VBD	refer O TermTag
to	TO	to O TermTag
as	IN	as O TermTag
serum	NN	serum GENE TermTag
amyloid	NN	amyloid GENE TermTag
P	NN	P GENE TermTag
(	(	( ( NUPOS
SAP	NN	sap GENE TermTag
)	)	) ) NUPOS
,	,	, , NUPOS
is	VBZ	be O TermTag
under	IN	under O TermTag
development	NN	development O TermTag
for	IN	for O TermTag
treatment	NN	treatment O TermTag
of	IN	of O TermTag
fibrosis	NN	fibrosis O TermTag
.	.	. . NUPOS

A	DT	a dt NUPOS
First-in-Human	NN	First-in-Human O TermTag
(	(	( ( NUPOS
FIH	NN	FIH O TermTag
)	)	) ) NUPOS
trial	NN	trial O TermTag
was	VBD	be O TermTag
performed	VBN	perform O TermTag
to	TO	to O TermTag
assess	VB	assess O TermTag
the	DT	the O TermTag
safety	NN	safety O TermTag
,	,	, , NUPOS
tolerability	NN	tolerability O TermTag
,	,	, , NUPOS
and	CC	and O TermTag
pharmacokinetics	NNS	pharmacokinetic O TermTag
of	IN	of O TermTag
single	JJ	single O TermTag
ascending	VBG	ascend O TermTag
intravenous	JJ	intravenous O TermTag
doses	NNS	dose O TermTag
of	IN	of O TermTag
PRM-151	NN	PRM-151 O TermTag
administered	VBN	administer O TermTag
to	TO	to O TermTag
healthy	JJ	healthy O TermTag
subjects	NNS	subject O TermTag
,	,	, , NUPOS
using	VBG	use O TermTag
a	DT	a dt NUPOS
randomized	VBN	randomize O TermTag
,	,	, , NUPOS
blinded	VBN	blind O TermTag
,	,	, , NUPOS
placebo	NN	placebo O TermTag
controlled	JJ	controlled O TermTag
study	NN	study O TermTag
design	NN	design O TermTag
.	.	. . NUPOS

Each	DT	each O TermTag
cohort	NN	cohort O TermTag
included	VBD	include O TermTag
three	CD	three O TermTag
healthy	JJ	healthy O TermTag
subjects	NNS	subject O TermTag
(	(	( ( NUPOS
PRM-151	NN	PRM-151 O TermTag
:	:	: : NUPOS
placebo	NN	placebo O TermTag
;	:	; : NUPOS
2:1	CD	2:1 O TermTag
)	)	) ) NUPOS
.	.	. . NUPOS

SAP	NN	sap GENE TermTag
levels	NNS	level O TermTag
were	VBD	be O TermTag
assessed	VBN	assess O TermTag
using	VBG	use O TermTag
a	DT	a dt NUPOS
validated	VBN	validate O TermTag
ELISA	NN	elisa O TermTag
method	NN	method O TermTag
,	,	, , NUPOS
non-discriminating	JJ	non-discriminating O TermTag
between	IN	between O TermTag
endogenous	JJ	endogenous O TermTag
and	CC	and O TermTag
exogenous	JJ	exogenous O TermTag
SAP	NN	sap GENE TermTag
.	.	. . NUPOS

At	IN	at O TermTag
a	DT	a dt NUPOS
dose	NN	dose O TermTag
level	NN	level O TermTag
of	IN	of O TermTag
10	CD	10 O TermTag
mg/kg	NN	mg/kg O TermTag
,	,	, , NUPOS
at	IN	at O TermTag
which	WDT	which O TermTag
a	DT	a dt NUPOS
physiologic	JJ	physiologic O TermTag
plasma	NN	plasma O TermTag
level	NN	level O TermTag
of	IN	of O TermTag
SAP	NN	sap GENE TermTag
was	VBD	be O TermTag
reached	VBN	reach O TermTag
,	,	, , NUPOS
two	CD	two O TermTag
additional	JJ	additional O TermTag
healthy	JJ	healthy O TermTag
volunteers	NNS	volunteer O TermTag
and	CC	and O TermTag
three	CD	three O TermTag
pulmonary	JJ	pulmonary O TermTag
fibrosis	NN	fibrosis O TermTag
(	(	( ( NUPOS
PF	NN	pf O TermTag
)	)	) ) NUPOS
patients	NNS	patient O TermTag
were	VBD	be O TermTag
enrolled	VBN	enrol O TermTag
enabling	VBG	enable O TermTag
comparison	NN	comparison O TermTag
of	IN	of O TermTag
the	DT	the O TermTag
pharmacokinetic	JJ	pharmacokinetic O TermTag
SAP	NN	sap GENE TermTag
profile	NN	profile O TermTag
between	IN	between O TermTag
healthy	JJ	healthy O TermTag
volunteers	NNS	volunteer O TermTag
and	CC	and O TermTag
PF	NN	pf O TermTag
patients	NNS	patient O TermTag
.	.	. . NUPOS

In	IN	in O TermTag
addition	NN	addition O TermTag
,	,	, , NUPOS
the	DT	the O TermTag
percentage	NN	percentage O TermTag
of	IN	of O TermTag
fibrocytes	NNS	fibrocyte O TermTag
(	(	( ( NUPOS
CD45	NN	CD45 O TermTag
+	CC	+ CC PennPOS
/	:	/ : NUPOS
Procollagen-1	NN	Procollagen-1 O TermTag
+	CC	+ CC PennPOS
cells	NNS	cell O TermTag
)	)	) ) NUPOS
in	IN	in O TermTag
whole	JJ	whole O TermTag
blood	NN	blood O TermTag
samples	NNS	sample O TermTag
was	VBD	be O TermTag
assessed	VBN	assess O TermTag
to	TO	to O TermTag
demonstrate	VB	demonstrate O TermTag
biological	JJ	biological O TermTag
activity	NN	activity O TermTag
of	IN	of O TermTag
PRM-151	NN	PRM-151 O TermTag
in	IN	in O TermTag
the	DT	the O TermTag
target	NN	target O TermTag
population	NN	population O TermTag
.	.	. . NUPOS

PRM-151	NN	PRM-151 O TermTag
administration	NN	administration O TermTag
was	VBD	be O TermTag
generally	RB	general O TermTag
well	RB	well O TermTag
tolerated	VBN	tolerate O TermTag
.	.	. . NUPOS

In	IN	in O TermTag
two	CD	two O TermTag
pulmonary	JJ	pulmonary O TermTag
fibrosis	NN	fibrosis O TermTag
patients	NNS	patient O TermTag
non-specific	JJ	non-specific O TermTag
,	,	, , NUPOS
transient	JJ	transient O TermTag
skin	NN	skin O TermTag
reactions	NNS	reaction O TermTag
(	(	( ( NUPOS
urticaria	NN	urticaria O TermTag
and	CC	and O TermTag
erythema	NN	erythema O TermTag
)	)	) ) NUPOS
were	VBD	be O TermTag
observed	VBN	observe O TermTag
.	.	. . NUPOS

PRM-151	NN	PRM-151 O TermTag
administration	NN	administration O TermTag
resulted	VBD	result O TermTag
in	IN	in O TermTag
a	DT	a dt NUPOS
6-to	JJ	6-to O TermTag
13-fold	RB	13-fold O TermTag
increase	VB	increase O TermTag
in	IN	in O TermTag
mean	JJ	mean O TermTag
baseline	NN	baseline O TermTag
plasma	NN	plasma O TermTag
SAP	NN	sap GENE TermTag
levels	NNS	level O TermTag
at	IN	at O TermTag
dose	NN	dose O TermTag
levels	NNS	level O TermTag
of	IN	of O TermTag
5	CD	5 crd NUPOS
,	,	, , NUPOS
10	CD	10 O TermTag
,	,	, , NUPOS
and	CC	and O TermTag
20	CD	20 O TermTag
mg/kg	NN	mg/kg O TermTag
.	.	. . NUPOS

The	DT	the O TermTag
estimated	VBN	estimate O TermTag
t1/2	NN	t1/2 O TermTag
of	IN	of O TermTag
PRM-151	NN	PRM-151 O TermTag
in	IN	in O TermTag
healthy	JJ	healthy O TermTag
volunteers	NNS	volunteer O TermTag
was	VBD	be O TermTag
30	CD	30 O TermTag
h.	NN	H. O TermTag
Pharmacokinetic	JJ	pharmacokinetic O TermTag
profiles	NNS	profile O TermTag
were	VBD	be O TermTag
comparable	JJ	comparable O TermTag
between	IN	between O TermTag
healthy	JJ	healthy O TermTag
volunteers	NNS	volunteer O TermTag
and	CC	and O TermTag
PF	NN	pf O TermTag
patients	NNS	patient O TermTag
.	.	. . NUPOS

PRM-151	NN	PRM-151 O TermTag
administration	NN	administration O TermTag
resulted	VBD	result O TermTag
in	IN	in O TermTag
a	DT	a dt NUPOS
30-50	CD	30-50 O TermTag
%	NN	% NN PennPOS
decrease	NN	decrease O TermTag
in	IN	in O TermTag
fibrocyte	JJ	fibrocyte O TermTag
numbers	NNS	number O TermTag
24	CD	24 O TermTag
h	NN	h NN PennPOS
post-dose	NN	post-dose O TermTag
.	.	. . NUPOS

This	DT	this O TermTag
suggests	VBZ	suggest O TermTag
that	IN	that O TermTag
administration	NN	administration O TermTag
of	IN	of O TermTag
PRM-151	NN	PRM-151 O TermTag
may	MD	may O TermTag
be	VB	be O TermTag
associated	VBN	associate O TermTag
with	IN	with O TermTag
a	DT	a dt NUPOS
reduction	NN	reduction O TermTag
of	IN	of O TermTag
fibrocytes	NNS	fibrocyte O TermTag
in	IN	in O TermTag
PF	NN	pf O TermTag
patients	NNS	patient O TermTag
,	,	, , NUPOS
a	DT	a dt NUPOS
population	NN	population O TermTag
for	IN	for O TermTag
which	WDT	which O TermTag
current	JJ	current O TermTag
pharmacotherapeutic	JJ	pharmacotherapeutic O TermTag
options	NNS	option O TermTag
are	VBP	be O TermTag
limited	VBN	limit O TermTag
.	.	. . NUPOS

The	DT	the O TermTag
pharmacological	JJ	pharmacological O TermTag
action	NN	action O TermTag
of	IN	of O TermTag
PRM-151	NN	PRM-151 O TermTag
should	MD	shall O TermTag
be	VB	be O TermTag
confirmed	VBN	confirm O TermTag
in	IN	in O TermTag
future	JJ	future O TermTag
research	NN	research O TermTag
.	.	. . NUPOS

